SCHEMBL29594176

CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C

nearest known ligand 0.69

Predicted protein targets (top 9)

	gene	UniProt	supporting neighbours	confidence
▸	RXFP1	Q9HBX9	4/20	0.69

▸	PTH1R	Q03431	10/20	0.67

▸	GLP1R	P43220	2/20	0.62

▸	CCKBR	P32239	1/20	0.62

▸	ECE1	P42892	1/20	0.62

▸	MUS81	Q96NY9	1/20	0.62

▸	GRPR	P30550	2/20	0.62

▸	KEAP1	Q14145	1/20	0.61

▸	IL23R	Q5VWK5	1/20	0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29595262	0.97	GLP1R (0.64)	RXFP1PTH1RGLP1RCCKBRECE1
SCHEMBL29595296	0.97	GLP1R (0.64)	RXFP1PTH1RGLP1RCCKBRECE1
SCHEMBL29595474	0.97	GLP1R (0.64)	RXFP1PTH1RGLP1RCCKBRECE1
SCHEMBL29594048	0.95	GLP1R (0.62)	RXFP1PTH1RGLP1RCCKBRECE1
SCHEMBL29594305	0.93	GLP1R (0.68)	RXFP1PTH1RGLP1RCCKBRECE1
SCHEMBL29595353	0.91	GLP1R (0.67)	RXFP1PTH1RGLP1RCCKBRECE1
SCHEMBL29594804	0.90	GLP1R (0.65)	RXFP1PTH1RGLP1RCCKBRECE1
SCHEMBL31694503	0.90	PTH1R (0.72)	RXFP1PTH1RGLP1RCCKBRECE1
SCHEMBL31182670	0.89	PTH1R (0.67)	RXFP1PTH1RGLP1RCCKBRECE1
SCHEMBL30862316	0.89	RXFP1 (0.80)	RXFP1PTH1RGLP1RCCKBRECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-11312756-B2	Engineered potent cytotoxic stapled BH3 peptides	THE TRUSTEES OF PRINCETON UNIVERSITY (US)	2022-04-26	—	—	US	claimed
US-11312756-B2	Engineered potent cytotoxic stapled BH3 peptides	THE TRUSTEES OF PRINCETON UNIVERSITY (US)	2022-04-26	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11312756-B2	Engineered potent cytotoxic stapled BH3 peptides	BID, MCL1, BCL2L13	RXFP1 4084/4885PTH1R 1105/4885GLP1R 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.